RESEARCH MONOGRAPH · KDC-MN-038

Nebracetam

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

46/100

Cholinergic-leaning racetam variant with M1 muscarinic activity, mostly forgotten

Nebracetam is one of those mid-tier racetams that had a real moment in Japanese pharmacology in the late 80s and then quietly disappeared. Yamanouchi developed it (originally WEB-1881) with the explicit goal of building cholinergic activity into the racetam scaffold, and they actually succeeded. The aminomethyl substitution gives it modest agonist activity at M1 muscarinic receptors, which is unusual for this compound class.

The interesting data, what theres of it, comes out of the early 90s. Spatial learning models in aged rats responded, scopolamine-induced amnesia was attenuated more than you'd see with piracetam, and the binding studies (Watanabe group and collaborators) showed real M1 affinity in the low micromolar range. There was even a small phase 2 in vascular dementia in Japan, but the results didnt push it across the line for approval and the program died around 1994.

What we like: it's a racetam with actual receptor selectivity, which is rare in this class. Most racetams have either no clear primary target or hit several at low affinity. Nebracetam at least has a story you can write down. The M1 muscarinic angle also lines up with cholinergic hypothesis-of-aging work in a way that makes it scientifically coherent.

What we dont like: the human data never matured, the mechanism work plateaued in the mid-90s, and the molecule basically fell off the field's radar before modern methods could be applied. Modern receptor pharmacology on this compound is genuinely sparse.

For research, this is a useful tool if you're studying M1 modulation specifically and want a compound with weaker selectivity than something like xanomeline. Its also worth having around if you're working on racetam-class SAR.

Sourcing is mediocre. A handful of Asian vendors produce it at gram scale, characterization quality varies, and impurity profiles are not as well-described as they should be. Run HPLC. If you're doing any quantitative work, run mass-spec too.

Underappreciated by the racetam crowd but not for nothing. The receptor pharmacology is actually interesting, even if the clinical story didnt land.

Evidence: 30
Mechanism: 60
Reliability: 50
Safety: 55
Sourcing: 50
Value: 45
Signal: 40
Staying power: 35

Plain-language summary Intrigue 30 / 100

Nebracetam is a phenyl-aminomethyl pyrrolidinone racetam developed in Japan. It is reported to enhance acetylcholine release through different mechanisms than other racetams. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phenyl-substituted aminomethyl pyrrolidinone

A 4-phenyl-pyrrolidinone with M1 muscarinic receptor agonist activity developed by Daiichi for cognitive impairment, discontinued in development.

Abstract

Nebracetam (WEB-1881-FU; 4-phenyl-2-pyrrolidinone-1-acetamide methyl derivative; CAS 97205-34-0; molecular formula C13H18N2O2; molecular weight 234.30) is a piracetam analog developed by Daiichi Pharmaceutical in Japan in the 1980s with structural features distinct from the classical racetam class. The compound includes a 4-phenyl group on the pyrrolidinone ring (similar to phenylpiracetam) and an aminomethyl modification on the acetamide side chain. Pharmacology shows partial M1 muscarinic acetylcholine receptor agonist activity in addition to the cholinergic facilitation typical of the racetam class. Phase 2 trials in mild cognitive impairment and elderly memory disorders showed positive but modest results; the development program was discontinued and the compound was never approved. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. Pharmacokinetics include plasma half-life of approximately 4 hours and good oral bioavailability. The clinical evidence base is limited; the M1 muscarinic agonist activity introduces a distinct profile from the open-chain racetams.

Mechanism of action

Partial M1 muscarinic agonist plus cholinergic facilitation typical of racetam class.

Reported research dose ranges

100 to 600 mg, as reported research dose ranges in the literature (Phase 2 trials).

References

Japanese Daiichi development program for WEB-1881-FU; sparse English literature.
Sakurai T, et al. Cholinergic effects of nebracetam. Neurosci Res 1990s.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-042

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Nebracetam

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs